Eleven major companies, some leading drugmakers included, came in the crosshairs of the investigation conducted by the National Anticorruption Directorate (DNA) in the case of corruption in the pharmaceutical sector, judicial sources told Agerpres.
The sources revealed that the list of the companies involved includes Roche Romania, a member of the ROCHE Multinational Corporation (drug manufacturer), Actavis SRL (drug manufacturer and distributor), Pfizer Romania SRL (biopharmaceutical company), Teva Pharmaceuticals Romania SRL (a pharmaceutical company), Novartis Pharma Services (drug manufacturer), Alvogen Romania SRL (drug manufacturer), Sandoz Pharma Services SRL (pharmaceutical company), GlaxoSmithKline Romania SRL (drug manufacturer), Egis International (pharmaceutical company), Romastru Trading (drug distributor), Glenmark Pharmaceuticals SRL (drug manufacturer).
According to the cited sources, the investigation revealed that former Roche Romania SRL CEO Dan Zamonea, former economic director with the same company Teodor Lucuta, and Actavis SRL CEO Dan Ivan had colluded for the prevalent prescription of drugs from Roche Romania SRL and Actavis Romania, so as to maximize company sales and profit.
Searches of homes and offices were conducted on Tuesday in this case at various locations in Bucharest and Ilfov, Sibiu, Mures, Salaj, Cluj, Bistrita-Nasaud and Timis counties.
Judicial sources indicated that involved in the illegal activities spanning the period 2012 – 2015 are heads of clinics and oncology wards, medical oncologists, coordinators and officials of the National Health Programme – Oncology subprogram, a chair of the Oncology Committee, an inspector of the Mures Public Health Department responsible for the control of pharmacies, and over 10 zonal representatives of drug companies.
Some of the doctors involved, who sit on hospital drug purchase committees, have allegedly claimed and received undue benefits, or the providers offered them such illegal perks.